- Home
- DIAX vs CTNM Comparison
DIAX vs CTNM Comparison
Compare DIAX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | DIAX | CTNM |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.1M | 480.5M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | DIAX | CTNM |
|---|---|---|
| Price | $14.10 | $12.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 100.4K | ★ 171.2K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.63 | $3.35 |
| 52 Week High | $15.85 | $16.33 |
Technical Indicators
Market Signals| Indicator | DIAX | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 43.21 |
| Support Level | $13.73 | $11.62 |
| Resistance Level | $14.45 | $13.40 |
| Average True Range (ATR) | 0.21 | 0.93 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 10.26 | 26.90 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.